Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

21 July 2014

FDA Advisory
No. 2014-056

SUBJECT: REITERATION OF PUBLIC HEALTH WARNING AGAINST THE USE OF UNREGISTERED FOOD SUPPLEMENT SEHAT BADAN POWDER



The public is again warned by the Food and Drug Administration (FDA) against the use of SEHAT BADAN powder manufactured by PJ. Nyior Koneng – Surabaya Indonesia.

The FDA has determined that the product contains sugar (sucrose and fructose), Diclofenac sodium, Paracetamol and Ibuprofen. Earlier, the FDA issued a public health warning against the use of the product (FDA Advisory No. 2014-006). However, despite the issuance of the earlier advisory the subject product is still found to be available in several places in the country, particularly in the Mindanao area.

As advertised online SEHAT BADAN is a herbal drink that "promotes and enhance general well-being and treat various diseases such as asthma, urinary stones, allergy, impotence, rheumatism, toothache and ulcer". These claims are not approved by the FDA and the subject product is not registered in this Office.

Distributors, retailers, hospitals, pharmacies, or clinics are instructed to discontinue further distribution, sale and use of the unregistered Sehat Badan product.

The field Food and Drug Regulation Officers are ordered to confiscate all unregistered food supplements, particularly SEHAT BADAN found in the market or in possession of individuals.

All local government units and law enforcement agencies are requested to ensure that these products are not sold or offered for sale in their localities or area of jurisdiction.

Civic Drive, Filinvest City, Alabang 1781 Muntinlupa, Philippines
Trunk Line +63 2 857 1900 Fax +63 2 807 0751
Website: www.fda.gov.ph Email: info@fda.gov.ph

To check if a product is registered with the FDA, please log in at www.fda.gov.ph and type in the name of the product in the search bar. To report any unregistered health product, please email us at report@fda.gov.ph. Consumer may also email the FDA at info@fda.gov.ph for any question or additional information.

Any adverse reaction experienced from the aforementioned product should be reportedly immediately to FDA by visiting www.fda.gov.ph. Look for the ADR Report tab and proceed to fill-out all of the required fields

KENNETH HARTIGAN-GO, MD
Acting Director General